[Drug therapy in bronchial carcinoma]

Area of Science:

• Oncology
• Pulmonology
• Medical Treatment

Context:

• Lung cancer treatment strategies are bifurcated based on histological classification: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
• SCLC is typically viewed as a systemic disease from diagnosis, necessitating chemotherapy as the primary treatment modality.
• NSCLC, characterized by localized growth, traditionally prioritizes surgery and radiotherapy, with systemic therapy reserved for advanced stages.

Purpose:

• To delineate the distinct therapeutic approaches for SCLC and NSCLC.
• To review the efficacy and application of chemotherapy in both SCLC and NSCLC treatment paradigms.
• To highlight emerging evidence for chemotherapy's role in earlier stages of NSCLC.

Summary:

• Chemotherapy, often a combination of cytostatic drugs over 4-6 cycles, dominates SCLC treatment, with treatment adjustments possible after the first cycle based on response. Intensification of induction chemotherapy in SCLC has not shown survival benefits.
• For NSCLC, surgery and radiotherapy are primary treatments for localized disease. Chemotherapy is mainly palliative in stage IV, but recent studies suggest benefits in stage III, particularly preoperative polychemotherapy with cisplatin.
• While promising, the positive results for stage III NSCLC chemotherapy require confirmation through larger, controlled clinical trials.

Impact:

• Provides a clear distinction between SCLC and NSCLC treatment protocols, aiding clinical decision-making.
• Identifies chemotherapy as the cornerstone for SCLC and highlights its evolving role in NSCLC management.
• Underscores the need for further research to validate the efficacy of neoadjuvant chemotherapy in advanced NSCLC.